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Nomenclature
3D: Three-dimensional
CTC: Circulating Tumor Cell, a tumor cell which is shed from the tumor or metastasis then
enters the bloodstream.
CT: Computed Tomography
CK: Cytokeratin is an intermediate filament expressed by epithelial cells which is used in this
project to tag CTC.
CD45: A differentiation that shows an extracellular protein expressed by leukocytes, used to tag
both neutrophils and leukocytes.
DTA: Distance-to-agreement
DAPI: 40, 6-diamidino-2-phenylindole (a nuclear stain)
EpCAM: Epithelial Cellular Adhesion Molecule, is an extracellular marker expressed by
epithelial cells which is used in this project to capture CTC.
IDD: Integral depth dose
IMRT: Intensity-Modulated Radiation Therapy
SSD: Source Surface Distance
TPS: Treatment planning system
WET: Water-equivalent thickness
SSPT: Spot scanning proton therapy
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Abstract
Due to its low side effects, proton therapy is rapidly developing around the world. However,
the time and labor it takes to deliver the treatment have prevented widespread use in the clinic
setting. For this reason, an automatic proton treatment analysis system is needed to improve
efficiency during the treatment process.
The challenge lies in improving the accuracy and speed of the current proton treatment
analysis system. The Range shifter correction factor is considered the same value under any
given condition in our treatment system. This approximate algorithm limits the accuracy of the
proton treatment analysis system. In addition, medical professionals spend a great deal of time
checking for errors. Errors, such as contouring mistakes and unnecessary spots are manually
reviewed during the treatment plans analysis process. At present, the dose calculation engine in
the analysis system requires five hours to complete one treatment plan. The calculation speed
limits our treatment capacity. Because the status of a tumor changes over the duration of the
treatment process, monitoring its status is imperative for delivering an accurate dosage. Our
research involves the development of an automatic proton treatment analysis system that uses
methods based on segmentation and registration algorithms to solve these problems.
The automatic proton treatment analysis system (and the accuracy and speed at which it
operates) has been validated in a clinical setting. Therefore, this analysis system could
potentially replace manual operation during the proton treatment plan quality assurance process.
The amount of time it takes to deliver proton therapy will be significantly reduced.
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1.1

Introduction

Fundamentals Of Proton Therapy
Cancer is the principal cause of death in the United States, second to heart disease. In

2013 it was reported that in the United States alone, 1,660,290 individuals were diagnosed and
580,350 individuals died from cancer related illness[1]. Radiation therapy is one of the main
methods used in treating cancer. Proton therapy is a type of radiation therapy. It is a treatment
that uses high-energy proton beams to treat tumors[2].
1.1.1 History Of Proton Beam Radiotherapy
In 1946, Robert R. Wilson was the first researcher to propose the use of protons for radiation
therapy at the Harvard Cyclotron Laboratory [3].The first patient was treated at Lawrence
Berkeley Laboratory in 1954. The Particle Therapy Cooperative Group (PTCOG) reports that
annually, about 55,000 patients worldwide are treated with proton therapy. This includes about
18,000 patients in the United States, where only five facilities exist for treatment.
Internationally, the number of operational and pending proton therapy centers is listed at around
50[4].
1.1.2 Physical Rationale
A proton is a particle that carries a positive charge. Protons can deposit energy into the
matter they pass through via ionization. From a radiobiological perspective, this imparted energy
can damage the DNA of cells. Toxic DNA lesions result in base and sugar modifications, singlestrand breaks, and double-strand breaks[5]. Damaged DNA may result in the cessation of cell
division.
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The main reason a proton beam is considered therapeutic for the treatment of tumors is
because protons have a well-defined penetration range. This advantage of proton therapy
compared to traditional radiation therapy has to do with the proton beam: It conforms to the
tumor three-dimensionally in a much better way[6]. As the proton transports through human
tissue, it slows down by interaction with electrons and loses energy. The point at which the
highest energy of deposit happens is called the “Bragg peak” (Figure 1.1)[7]. Physicians want the
Bragg peak’s location to coincide with the tumor mass, thus directing the most energy towards
killing tumor cells.

Figure 1.1 Depth-Dose distribution of a broad proton beam in water[7]
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1.1.3 Treatment Planning System

Figure 1.2 Eclipse treatment planning system[8]
The Treatment Planning System (TPS) is a key part of proton therapy. Oncologists will
identify tumors from the images presented in the system (Figure 1.2). The system will develop a
plan for delivering proton beams to the tumors based on beam line routes. TPS also calculates
the expected dose distribution in the patient’s tissue. Critical structures of the human body could
be protected by optimized beam placement. These beam routes are calculated via complex
programs[9]such as the Eclipse Treatment Planning System (Eclipse: Version 8.917 by Varian
Medical Systems, Palo Alto, CA). Eclipse is the commercial TPS used at the MD Anderson
Cancer Center. The calculation method of the system is a trade secret. Our proton treatment
analysis system will implement the type of quality assurance necessary for proton treatment
plans created by the TPS.
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1.1.4 MD Anderson Cancer Center Proton Therapy Facility
MD Anderson Cancer Center proton-therapy facility consists of three main components: an
accelerator with an energy selection system, a beam transport system, and a beam delivery
system (Figure 1.3).

Figure 1.3 Proton Therapy Center-MD Anderson Cancer Center, Houston[10]
Protons are generated inside the accelerator and sent out via the beam delivery system. At
the source of the accelerator, hydrogen atoms are divided into electrons carrying a negative
charge and protons with a positive charge[11]. The protons are then shot through a vacuum tube
into a linear accelerator, where the energy increases to 7 million electron volts per microsecond.
To acquire the range of depth necessary for the proton to be delivered, proton beams accelerate
4

to 70 to 250 million electron volts before being sent out from the synchrotron.

A series of

magnets in the beam delivery system will guide the protons to move in the assigned direction,
focusing on the appropriate treatment area [12]. A Gantry revolving 360 degrees could deliver
the beam to the patient from any angle (Figure 1.4). There are a series of software and hardware
control systems used to implement the whole system (Figure 1.3).

Figure 1.4 MD Anderson proton delivery system
1.1.5 TOPAS: Particles Simulation Tool
TOPAS is used to make advanced particle simulation of all forms of radiotherapy. It is
applied to model proton treatment plans in this research. We were able to configure pre-built
components (such as nozzles, patient geometry, dosimetry, range shifter, and imaging
components) to simulate proton treatment using TOPAS [13]. Dose distribution matrices for the
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range correction factor in Chapter 2 and fast dose calculations in Chapter 3 were acquired by
simulation of the TOPAS.
1.1.6 Matrixx: Standard Clinical Dose Measurement Device
Matrixx (MatriXXTM, ScanditronixWellhofer, Schwarzenbruck, German) [14] is a proton
dose measurement device. All of the clinical dose measurements in this dissertation are
implemented by Matrixx (created by IBA Dosimetry). MatriXX is a two-dimensional array of
1020 (32×32) vented, parallel plate pixeled ion chambers. Each chamber has a diameter of 4.5
mm and a sensitive volume of 0.08 cc. The center-to-center separation between the chambers is
7.62 mm, and the active field size is 24×24 cm2.
1.2

Fundamentals Of Circulating Tumor Cells Isolation Technology
Circulation tumor cells (CTCs) detection and isolation method will be used to monitor tumor

status in guiding proton treatment. The concept of CTCs and CTCs isolation device we used will
be introduced as follows.
1.2.1 Circulating Tumor Cell
Metastasis is the main cause of cancer-related death in patients with solid tumors [14] .
Circulating Tumor Cell (CTC) is a tumor cell which is shed from the tumor, then enters the
bloodstream (Figure 1.5). CTC is regarded as key in interpreting cancer metastasis since CTC
can potentially provide information about the different cancers and mechanisms of
metastasis[15] . Increasing evidence suggests that CTC monitoring could guide tumor treatment
[16] [17] . Furthermore, the heterogeneous nature of CTCs provides inclusive, non-invasive
means for characterizing tumor molecular subtypes such as phenotype. Genetic information can
be used to provide critical information used to guide cancer treatment [18, 19]. Circulating
cancer cells are detected in common epithelial cancers, including breast, prostate, and lung [20].
6

Cytokeratins, prostate-specific antigen (PSA), mucin-1 (MUC-1), HER2, AFP (-fetoprotein), and
the CEA (carcinoembryonic antigen) gene family among others are used as tumor cell–specific
markers [21].

Figure 1.5 Schematic view of the metastatic process showing CTC transit: the CTCs exit the
primary tumor, intrastate into the bloodstream, circulate, and extravagate into a secondary site
where they may ultimately achieve different fates including dormancy and full-blown metastasis.
[22] . Nature Publishing Group.
1.2.2 NanoVelcro Cell-affinity Substrates: CTCs Isolation Device
Circulating tumor cells can be isolated during the process of metastasis. Because CTCs are
tremendously rare (there is approximately one CTC per billion normal blood cells circulating in
patients with advanced cancer[23]), the enrichment of CTC is a very important step in the
detection procedure. Motivated by nanoscale interactions observed in the tissue
microenvironment, nanosubstrates (CTC captured, agent-coated, nanostructured substrates) were
utilized to restrain CTCs with high efficiency. The working mechanism in NanoVelcro cell-
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affinity substrates describes the relationship between a cell surface antigen and a nano surface
antigen. When both are tangled together, strong binding occurs and the cell is captured [24] .
Figure 1.6 shows the principle of the chip. CTCs can be enriched on the chip after most blood
cells are removed by solution fluid. More information about nanosubstrate system is introduced
in reference [23].

Figure 1.6 Nano cell-affinity substrates working mechanism [23]
1.3

Scope Of Dissertation
This dissertation will summarize our current research and describe the automatic proton

treatment analysis system step by step (Figure 1.7).
Chapter 2 will provide information about the range shifter correction factor and apply the
correction factor data set to proton treatment plans, showing improvement in dose calculation
accuracy of the proton treatment analysis system. (Figure 1.7 (1)).
Chapter 3 will introduce the concept of small spot clusters and apply an analytical method
toward the detection of errors in treatment plans, thereby replacing manual detection and
improving the work efficiency of medical professionals (Figure 1.7 (2)).
Chapter 4 will provide a fast dose calculation algorithm to implement high speed dose
calculations. The calculation results will be used for quality assurance (Figure 1.7(3)).
8

Chapter 5 provides an automatic CTC analysis program. This CTCs detection and isolation
method could be used for monitoring the status of tumors, in which results could be used to
guide the proton treatment process (Figure 1.7(4)).
Chapter 6 will summarize this research and discuss the future research plan.

Figure 1.7 Automatic proton treatment analysis system
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2

Dose Calculation For Scanning Spot Proton Therapy With Application Of
Range Shifter

2.1

Abstract

Purpose: A correction factor data set is built to improve dose calculation quality for proton
treatment analysis system that makes use of a range shifter, sometimes called an energy absorber.
Material And Method: The particle simulation tool TOPAS was used to simulate the range
shifter model for correction factor calculation. A range shifter, Bragg peak chamber, and water
scanning system were used to validate the correction factor method. The synchrotron-based spot
scanning proton therapy system has an energy range of 72.5 to 221.8 MeV. A brain case
treatment plan was used to demonstrate the clinical significance of the correction factor data set.
Result: The beam parameters in simulations were finely tuned to make the simulated dose
distributions match the measurements with the mean difference in the magnitude of 1.0%. The
TOPAS generated correction factors for different beam energies and different depths in the water
phantom show that for each specific beam energy the dose correction factor increases with the
increase of air gap and decreases with the increase of depth in water, and larger correction
factors are needed for higher beam energies. The gamma test pass rate for the selected brain
treatment plan was improved from 80.4% to 97.8% after applying the dose correction factors.
Conclusion: The range shifter correction factor data set is a practical, low-cost solution that
could significantly improve the dose calculation accuracy for SSPT clinics.
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2.2

Introduction
Spot scanning proton therapy (SSPT) is used to deliver intensity-modulated proton therapy

(IMPT) in MD Anderson Cancer Center. The three-dimensional volume of the tumor target is
dynamically scanned by, sort of, painting the target with proton Bragg peaks layer-by-layer [25,
26]. Two scanning magnets are used to control the lateral beam position (X and Y) and variable
energies of protons extracted from the synchrotron are applied to control the depth (Z). All layers
are scanned sequentially from the highest to the lowest energy, that is, from the distal edge to the
proximal edge of the tumor target.
The synchrotron-based SSPT beam delivery system (PROBEAT Proton Beam Therapy
System, Hitachi America, Ltd., Tarrytown, NY, USA) at the University of Texas M. D.
Anderson Cancer Center Proton Therapy Center in Houston, Texas (PTCH) can produce 94
energies ranging from 72.5 MeV to 221.8 MeV, corresponding to proton ranges of 4.0–30.6 cm
in water[25] and similar ranges for other materials based on their water-equivalent thickness
(WET). The maximum field size is 30 × 30 cm2 at isocenter. For patients with targets shallower
than 4.0 cm WET, a range shifter (sometimes called an energy absorber) is used to reduce the
range of higher energy beams to the desired range, as shallow as 0.3 cm WET. Besides, a highenergy beam has a relative small spot size; therefore, using range shifters and high-energy beams
together can reduce the dose penumbra to the desired locations in the targets [12]. The range
shifter used at PTCH is made of ABS (Acrylonitrile butadiene styrene) resin (ρ = 1.04 g/cm3)
and has a WET of 6.7 cm. (Figure 2.1.A) [12]. For the PTCH system, the range shifter is placed
at the distalmost edge of the beam nozzle (Figure 2.1.A). The nozzle, along with the range
shifter, can be extended along the beam direction, allowing the distal edge of the nozzle to have a
position anywhere from isocenter to 38 cm proximal to isocenter. In this paper, air gap is defined
11

as the distance from the range shifter distal surface to target’s proximal surface as shown in
Figure 2.1A. The air gap changes as range shifter position changes, assuming the target position
stays fixed.
In our clinical practice, we found that the dose calculation accuracy of the treatment
planning system (TPS) for treatment plans using the range shifter is lower than the average
accuracy of all treatment plans [27]. We found that the dose delivered to the target, for a given
depth and beam energy, varies with air gap (the distance between the range shifter distal surface
and target proximal surface (Figure 2.1B). To our knowledge, this topic has seldom been
discussed previously in the literature. It seems that until now, the TPS and other dose engines,
have simply assumed an air gap of 0 [28, 29]. This deficiency of the dose calculation algorithm
caused noticeable discrepancies in patient-specific quality assurance results. In this paper we
propose to build a correction factor data set for a higher accuracy dose calculation.
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Figure 2.1 (A) Illustration of IDD measurements with different air gaps between the range
shifter and the water phantom. (B) The measured IDD distributions in water for 219.3 MeV
protons with air-gap sizes of 0 cm, 10 cm, 20 cm and 30 cm. The enlarged view in the bottom
panel shows the differences with different air-gap sizes. The Bragg peak chamber (scoring radius
= 4.08 cm) was used to perform the IDD measurements along the z axis.
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2.3

Method and Materials

Figure 2.2 (A) Setup of the IDD measurements. The range shifter is mounted on the snout of the
scanning proton nozzle. The snout can be retracted and extended to provide different air-gap
sizes between the range shifter and the water phantom. The Bragg peak chamber is positioned
along the central axis. It is mounted on the automatic scanning system of the water tank to
measure dose at different locations. (B) The setup used in TOPAS simulations. Two different
types of virtual detectors are built. A cylinder with radius of 4.08 cm and thickness of 1 mm is
used to model the Bragg peak chamber. Because the spot sizes of low-energy beams are larger
than the size of the Bragg peak chamber. A larger layer of 25 cm * 25 cm * 1 mm is modeled as
a sensitive detector to capture most of the transporting particles.
2.3.1 Evaluation And Simulation Tools
2.3.1.1 Gamma test: Dosage calculation validation method
The gamma test is applied to validate the accuracy of dosage calculation results used in
proton therapy. It is also used to validate the accuracy of the range shifter correction factor and
the fast dose calculation algorithm presented in this dissertation.
Gamma test can assess dosage distributions through a composite analysis of distance-toagreement (DTA) and difference in dose amounts [30]. The technique integrates both DTA and
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dose difference analysis and provides a numerical gamma index as an evaluation value of the
agreement between two datasets.
Range uncertainties in the delivery of proton therapy result from both the conversion of
computed tomography (CT) in Hounsfield units to proton stopping power [31] and image
artefacts [6]. Therefore, an uncertainty of approximately ±3% is considered in our clinical
practice[32]. The standard for the gamma test is equal to 90% of the testing points passed based
on a 3 mm distance to agreement and a 3% difference in dose amount.
The pass rate of Gamma test stands for the difference between measurements data (rm) for
each reference point and calculation data (rc). The value is usually scaled to acquire
dimensionless quantitates. In this paper the value is set as 3 mm-3%, which means the specific
point is within 3 mm in comparison to the reference point and dose difference is within 3%. This
criteria is used in the pass/fail evaluation for each point [33]. Equation 2.1 shows the calculation
method:

γ =√

r2 (→ → )
r m, r c
∆d2
m

+

δ2 (→ → )
r m, r c

Eq.2.1

∆D2
m

where
r(→ → ) =|→ −→ |
r m, r c

rc

rm

and
Dc is the distance between the calculation data position and test point position
Dm is the distance between measurement data position and test point position

δ (→ → ) = Dc (→ ) − Dm (→ )[33]
r m, r c

rc

rm
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2.3.2 The Concept Of Dose Correction Factor
In the current dose calculation algorithm, the integral depth dose (IDDz) is considered to
only be related to depth(z cm)[34].Doses delivered to a target after traversing different air gaps
(a cm) are all considered to be the same value as when the air gap is equal to 0 cm(IDD(z,0)).
Based on the IDDs acquired by measurements of different air gaps (Figure 2.1B), this
assumption is not accurate.
The IDD is dependent upon both depth (z cm) and air gap (a cm).We take the current
standard dose calculation IDD (z, 0) and improve it by adding a dose calculation correction factor
(Ga) related to the air gap (a cm) to acquire a more accurate IDD (z, a).
IDD (z, a) =IDD(z,0) ×（1-G(z, a)）

(1)

It is convenient for us to understand how much dose change from current dose calculation
method IDD(z,0) to IDD(z,a). G(z,a) stands for the ratio of dose loss related with the air gap (a cm),
therefore (1-G(z,a)) will be the ratio of dose deposited on the target at the depth z in the target
after transporting through the range shifter.
Where:
IDD is the integral depth dose
z is the depth in the water phantom
G(z,a) is the correction factor corresponding to the air gap size (a cm) at depth(z cm)
G(z,a) is calculated using equation (2.2)
𝐺a =

𝐼𝐷𝐷0 −𝐼𝐷𝐷𝑎
𝐼𝐷𝐷0

Where:
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(Eq 2.2)

𝐼𝐷𝐷0 is the integral depth dose with air gap a=0 cm (Figure 2.1.A)
𝐼𝐷𝐷𝑎 is the integral depth dose range when an air gap a (cm) exists between range shifter
distal surface and water phantom proximal surface (Figure 2.1.A)
𝐺z,ais the ratio of 𝐼𝐷𝐷𝑎 difference to 𝐼𝐷𝐷0
𝐺a for all energies with different air gap (a cm) are calculated for clinical plan simulation.
The main purpose of equipping the range shifter is to take the advantages of the relatively
small spot sizes of high-energy beams. In this way, smaller lateral penumbrae can be achieved.
When the beam energies are lower than 151.0 MeV the range shifter is rarely used. Therefore, in
this study, we only calculate correction factors for proton energies ranging from 151.0 MeV to
228.1 MeV (30 proton energies in total).
2.3.3 IDD Measurements In The Water Phantom
To validate the range shifter simulation model, the dose delivered to the simulated water
phantom is compared to the dose delivered to a water tank that is measured using a Bragg peak
ion chamber (model 34070, PTW-Freiburg, Freiburg, Germany) (Figure 2.2A). The chamber has
a diameter of 81.6 mm and a sensitive volume of 10.5 cm³. The WET of the chamber entrance
window is 4 mm [35, 36] .The range shifter is positioned to create air gaps of 0 cm, 10 cm, 20
cm, and 30 cm for the simulation. The IDDs for 219.3 MeV with 0 cm, 10 cm, and 30 cm air
gap, as well as those for 151.0 MeV and 181.3 MeV with a 30 cm air gap, are measured with the
water tank [37].
An 82 mm diameter detector is placed in the water phantom of the simulation model (Figure
2.2B) to simulate the IDD curve measured by the Bragg peak chamber. The simulation results
are then compared to the measurement results [13].
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Integral depth dose (IDD) are applied to compare dose calculation results with the
measurement results of the dose delivered to the water tank.
2.3.4 Setup Of Simulations In TOPAS
𝐼𝐷𝐷0 and 𝐼𝐷𝐷𝑎 are acquired by our simulation model. In our previous publication, we built
a beam simulation model for the PTCH spot scanning treatment system[38]. The model provides
accuracy with multi-energetic field simulations showing errors <5%. The 2% - 2 mm gamma
analysis of the clinical plan has a pass rate >97%, while the 3% - 3 mm analysis has a pass rate
of 99.9%.
The simulation platform Tool for Particle Simulation (TOPAS) [39, 40] is used to build the
beam model. TOPAS (Version 2.0.p3) is a based on the general-purpose Monte Carlo toolkit
Geant4 (Version 10.2) [41, 42] , which has been broadly used in proton and particle therapy
related research [43-45]. The QGSP_BIC_EMY physics list was selected to provide the accurate
dose distribution [46-48]. The parameters of the geometrical model are as displayed in Figure
2.1a. A water phantom with x, y, and z dimensions of 25 cm, 25 cm, and 35 cm, respectively
(Figure 2.1A), was built in the simulation. For dose calculations, the voxel has a volume of 1 × 1
× 1 mm3 in the water phantom [49]. The xy-plane of the water phantom is equal to the field size
of the ionization chamber array, MatriXX (IBA Dosimetry, Schwarzenbruck, Germany), which
is used in our measurements for patient quality assurance (Refer to section 1.1.6). The z
dimension of the water phantom is longer than the range of the maximum beam energy 221.8
MeV. 5x106 histories were generated per run by the simulations to make the statistical
uncertainty < 1%. A double Gaussian beam source model is built for this simulation. The spatial
spread of each beam source decreases as beam energy increases. The spatial spread of the first
source, 𝝈𝟏 ,was set to range from 5.2 mm to 11.2 mm for beam energies. For energies between
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74.5 MeV and 150.0 MeV, the spatial spread of the second source, 𝝈𝟐 , was set to range from
12.5 mm to 27.2 mm. For energies above 150.0 MeV, the second source was not needed. For
energies lower than 80 MeV, the weight for the second source is 0.12. For energies from 80 MeV
to 150 MeV, the weight of the second source is 0.08 [39, 50, 51].
The 6.7 cm WET range shifter was modeled between the proton source and the water
phantom. The range shifter can be moved in the beam direction to form different air gap
distances between the distal surface of the range shifter and the proximal surface of the water
phantom. The water phantom proximal surface is fixed at isocenter (Figure 2.1A). Simulation
results for all required energies with different range shifter positions are used for correction
factor calculation. Two different types of virtual detectors are built in the water phantom (Figure
2.2B). A cylindrical scorer (water) with the radius of 4.08 cm and the thickness of 1 mm is used
to model the Bragg peak chamber. Because the spot sizes of low-energy beams are larger than
the size of the Bragg peak chamber. A water layer of 25 cm x 25 cm x 1 mm is modeled as the
sensitive detector to capture most of the transporting particles. When comparing with the
measured IDD, the simulated IDD from the virtual cylindrical detector is used. When calculating
dose correction factors, the simulated IDD from the large virtual cubic detector is used. The
number of particles (primary protons and other secondary particles) arriving at the entrance plane
of the water phantom is also scored.

2.3.5 Correction Factor Validated By Clinical Plan
To validate the accuracy of the correction factor, a clinical head and neck treatment field
was simulated and the correction factor G(z,a) is applied to the dose calculated by the standard
algorithm using Equation (2.1).
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In our dose calculation algorithm for treatment plans not using the range shifter, the
simulation dose (Gy/history) is converted to real dose (Gy/MU) by following equation (2.3).

𝐷𝑜𝑠𝑒𝑟𝑒𝑎𝑙 =

𝐼𝐷𝐷𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡
𝐼𝐷𝐷𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛

× 𝐷𝑜𝑠𝑒simulation

(Eq 2.3)

The improved dose calculation equation applied to the treatment plan calculation will be:

𝐷𝑜𝑠𝑒𝑟𝑒𝑎𝑙 =

𝐼𝐷𝐷𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡
𝐼𝐷𝐷𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛

× (1 − 𝐺z,a ) × 𝐷𝑜𝑠𝑒simulation

(Eq 2.4)

𝐷𝑜𝑠𝑒𝑟𝑒𝑎𝑙 is the dose at specific point at depth z cm.
𝐼𝐷𝐷𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡 is the configuration integral depth dose per MU(monitor unit) for proton
energy E MeV
𝐼𝐷𝐷𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛

is the simulation integral depth dose Gy/history for proton energy E MeV

𝐺z,a is the correction factor for depth z cm and air gap a cm
(1 − 𝐺z,a ) is applied in equation (2.4) to correct the 𝐼𝐷𝐷𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡 from air gap 0 cm to air
gap a cm.
The result is compared to the patient-specific quality assurance measurements of that were
performed by a clinician for this plan. The treatment field gantry angle was 300̊, with an energy
range of 98.0 MeV to 173.7 MeV. The field has 1821 scanned spots. The measurement data for
this plan was acquired using a solid water phantom with a MatriXX 2-dimensional ion chamber
20

array. For each beam, 250,000 events were generated. Gamma test is performed using 3% - 3
mm evaluation criteria. To accomplish this, the 7.2mm × 7.2mm grid is bilinearily interpolated to
a 1 mm × 1 mm grid. The threshold level of the dose for the gamma analysis was set to 10% of
the maximum dose.
2.4

Result

2.4.1 Simulation Results Validated By IDD Measurements In The Water Tank
The measurement data of 219.3 MeV is compared with the simulation data from the detector
in the model simulation results (30 cm and 10 cm) (Figure 2.3.A&B), yielding a mean difference
of 0.9% and 1.0%, standard deviation are 0.9% and 0.9%. Measurement data of 151.0 MeV
(Figure 2.3C) and 181.1MeV, both with air gaps of 30 cm (Figure 2.3D) are compared with
simulation data. The mean differences are 1.3% and 1.2%, standard deviation are 1.1%and 0.5%,
respectively.
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Figure 2.3 Comparisons of IDD distributions between simulations (solid lines) and
measurements (red dots) for different proton energies with different air gaps. MU stands for
monitor unit. Simulation results are from the virtual cylindrical detector with the same dimension
of the Bragg peak chamber used in the IDD measurements.
2.4.2 The Simulation Results From Large Scorers
We also performed the simulations with large scorers (25 cm x 25 cm x 0.1 cm) to score
IDDs and the acquired data are used to calculate the dose correction factors at different depths
for different air gaps. The simulation results for 221.8 MeV protons with different air gaps are
compared in Figure 2.4. It demonstrated that with the increase of air gap distance, the dose from
entrance plane to plateau region is decreased. This is due to the lateral scattering of beam passing
through the range shifter. Since the distance between source plane and the entrance plane of the
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range shifter is very long (Figure 2.1A), we can assume the scattering angle of beam exiting the
range shifter is not affected by the distance between source plane and the entrance plane of the
range shifter. After passing through the range shifter, the scattered beam will travel in the air gap
and then enter the water phantom. Obviously, a longer air gap distance will cause a larger lateral
spread of beam spot, which may result in the loss of particles arriving at the entrance plane of the
water phantom. We have investigated the number of different particles (primary protons and all
other secondary particles) arriving at the entrance plane of the water phantom. The number of
primary protons and the number of secondary particles are listed in Table 2.1. Our data show that
the number of primary protons decreases slightly with the increase of air gap, but the number of
secondary particles can be largely affected by the air gap. More secondary particles are scattered
laterally away from the central axis and may not enter the phantom, resulting in a decrease of
energy deposition in the scorer (25 cm x 25 cm x 0.1 cm). This turns into the decrease of total
dose as shown in Figure 2.4. The simulated dose data are then used to calculate the dose
correction factors.
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Figure 2.4 The IDD distributions of 221.8 MeV protons with different air gaps. In the Monte
Carlo simulations, the dimension of the soccer is 25 cm x 25 cm x 0.1 cm. A larger air gap can
result in a lower dose from the entrance to the plateau region.
Table 2.1 The number of particles at the entrance plane of the water phantom with different air
gaps. The initial number of source protons is 106.
Air gap
Number of
primary protons
Number of
secondary particles

0 cm
935164

10 cm
933866

20 cm
930547

30 cm
929027

213349

127951

84720

64867
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Figure 2.5 Simulation results (A) Correction factor depth profile for proton energy 221.8 MeV,
171.3 MeV and 153.2 MeV with air gap 30 cm (B) Correction factor depth profile for proton
energy 221.8 MeV with air gap 10 cm, 20 cm, 30 cm (C) Correction factor validation by
measurement result (D) Correction factor effective range for proton energy 221.8 MeV.
With a constant air gap, the correction factor decreases as energy decreases. The largest
correction factor is 0.11 for proton energy 221.8 MeV at depth 0 cm and air gap 30 cm (the
highest air gap that can be measured for our system) (Figure 2.5A).
With a constant air gap and energy, the correction factor decreases as depth increases
(Figure 2.5B).The correction factors are only calculated for proton energies from 150 MeV to
228.1 MeV (30 proton energies in total) for this paper because the correction factor of energies
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lower than 150 MeV are too small (<0.01 for energies with ranges <2 cm) to count in the dose
calculation (less than 0.01 after depth 2 cm).
Correction factor of 219.3 MeV measurement and calculation maximum difference is 0.7%
when the correction factor is higher than 1.0%. Because the accuracy requirement for clinical
application is the dose deviation shall be within 3%, the result would satisfy our clinical
requirement (Figure 2.5C).
The correction factor for each proton energy is a random number at depth after Bragg peak
presents (Figure 2.5D) which means the effective range of the correction factor is from target
surface to the Bragg peak depth in the target.
2.4.3 Proton Fluence Simulation Results From Scorers

Figure 2.6 (A) Fluence of water phantom surface vs range shifter position (air gap) (B) Peak A
is fluence of the water phantom surface when air gap equals to 0 cm，peak B is fluence when air
gap equals 30 cm

For energy 219.3 MeV, at the water phantom surface (Depth=0 cm), 500,000 proton partials
histories were generated by the simulations. The proton fluence decreased from 7.95 /mm2 to
26

7.582 /mm2 as the air gap increased from 0 cm to 30 cm (Figure 2.6A). The range shifter
prevents some of the protons from reaching the water phantom, as some are lost in the air gap.
This is due to the beams being scattered after passing through the range shifter .That is why the
dose, calculated at corresponding test points downstream from the range shifter, decreases as the
air gap increases. (Figure 2.5B).
From Figure 2.6B we find that the fluence distribution of peak A, with an air gap of 0
cm, is different than that of peak B, which has an air gap of 30 cm. The blue part of peak A is
much smaller than the blue part of peak B which means that the low fluence area in A is much
smaller than that region in B. When the air gap is greater, the protons spread in a larger area.
Peak A is much higher than peak B which also supports that when the air gap is smaller, the
protons distribute in a more narrow area.
2.4.4 Correction Factor Validated By Clinical Treatment Plans
The calculation from the TPS (Eclipse Versions 8.917, Varian Medical Systems, Palo Alto,
CA,USA) resulted in a gamma result that was lower than our clinical requirement (gamma pass
rate of 90% using 3% - 3 mm evaluation criteria). After applying the correction factor, the
gamma pass rate increased from 80.4% to 97.8%. Because the high proton energies are shifted
by the range shifter in the clinical plan, a correction factor was used on the dose calculation
result. Figure 2.7 shows that for the a field at a depth of 11.9 cm, and using evaluation criteria of
3% - 3 mm the gamma pass rate increased from 80.4% to 97.8%.
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Figure 2.7 Measurement compared with TPS and measurement compared with simulation applied
correction factor at depth 11.9 cm using gamma analysis. (A) TPS compared with measurement
result using gamma analysis. (B) Gamma pass rate histogram of TPS vs. measurement (C)
Simulation with correction factor compared with measurement result using gamma analysis. (D)
Pass rate histogram of simulation with correction factor vs. measurement
Only energies higher than 166.2 MeV could deliver dose to a depth of 11.9 cm after
traversing the 6.7 cm WET range shifter, a total depth of 18.6 cm WET. According to the
effective range of the correction factor (Figure 2.5D), the correction factor applies to energies
higher than 166.2 MeV in the treatment plan. (Table 2.2).
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Table 2.2 Correction Factor for Air Gap a=30.0 cm, depth=11.9 cm
Proton
Energy(MeV)
173.7
171.3
168.8
166.2

Factor(Ga)
0.0110
0.0050
0.0021
0.0014

The other cases are tested for the correction factor, the pass rate improved from 80.0% to 99.8%
at depth 5.0 cm for a head and neck plan. The pass rate improved from 87% to 93.7% for a Thorax
plan (Table 2.3).

Table 2.3 Comparisons of Gamma pass rate for a thorax plan and a head&neck plan before and
after applying correction factors.
Case
Type

Head
neck
Thorax

2.5

Gamma Pass Rate (%)

Air
Gap(cm)

Depth(cm)

30
20

Before

After

5

80

99.8

3.7

87

93.7

Discussion
According to the results of Table 2.3, the dose calculation accuracy improved by the

correction factor well mostly on distal and proximal of the target. This is because only high
energy protons can deliver dose to the distal part of the target and the high energy proton all need
to apply correction factors. At proximal part, even the dose weight from high energies proton is
low, but the correction factor is bigger than in distal part (more than 3% dose difference).The
quality assurance for treatment plan fail mostly occurs at distal and proximal because the
analytical model in treatment planning system didn’t count the fluence lost. This correction
factor data set shall be added to any calculation related with this type of range shifter.
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It is difficult to acquire continuous correction factor data from measurement because the
labor and beam cost are very high. The range shifter model could be used to do patient-specific
dose calculations, but it would be as slow as the common Monte Carlo method. The majority of
TPSs still use analytical dose calculation algorithms for optimization and final dose calculation.
TOPAS simulation could help to improve the dose calculation algorithm by modeling the
experimentally challenging configurations. Preparing a correction factor data set by this range
shifter model simulation is, perhaps, the most practical way to improve the accuracy of current
dose calculation engines. Applying the factors to specific proton energies based on the air gap,
dose verification simulation accuracy could be improved without heavily modifying the current
system.
2.6

Conclusion
We found that proton fluence was being lost in the air gap in our clinical practice, which led

to a reduction of dose to the target. We propose to build a correction factor data set to improve
the accuracy of current range shifter modeling for dose calculation of proton treatment analysis
system. The calculation results match the measurement results acquired using a Bragg peak ion
chamber in a water tank. By incorporating the correction factors into the current dose calculation
method, the dose calculation accuracy of patient treatment fields using a range shifter can be
significantly increased. The correction factor data set could be generated in our range shifter
model and applied for future dose calculation. This method could likely be applied to our proton
treatment analysis system in a flexible way.
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3

An Automated Quality Management Of Spot Cluster Algorithm As A
Safety Procedure For Implementing Pencil-Beam Scanning Proton
Therapy

3.1

Abstract

Purpose: To develop an automated quality management to detect the potential error in the
proton spot scanning delivery process based on knowledge extraction of the previous delivered
fields.
Methods: 1297 treatment fields from 2014-2016 in our center were analyzed for the knowledge
extraction. Proton spot distributions are transferred to binary matrix. A connected-component
labeling algorithm is developed to label all the spot clusters.
Result: The threshold for small spots clusters is established with algorithm analysis. Once the
field is identified as the small spots cluster that is less than the threshold, an alert will be
automatically sent out to prevent the potential accident or other mistakes by the filters developed
in house in our center. Three types of error will be automatically detected by the proposed
algorithm: 1) the contouring error for the targets; 2) the unnecessary small cluster at the distal
end causing the dose distribution not passing the quality assurance (QA) criteria; and3)
Abnormal high dose region outside target.
Conclusion: The automated quality assurance procedure based on data mining of the previous
delivered fields can prevent the errors and improve the quality assurance process for the proton
spot scanning delivery.
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3.2

Introduction

The narrow proton beam used in active beam delivery in proton treatment defines as spots.
Spots are scanned laterally by magnetic steering in the plane perpendicular to the beam direction,
creating a large field free from scattering elements such as aperture or compensation [52, 53] .
Monoenergetic spots with different energies form a synchrotron that can be stacked to deliver the
specified dose distribution along the direction of the beam. It is possible to modulate the intensity
of each spot in order to deliver a conformal three-dimensional (3-D) dose to the target volume [6,
54-57]. 3-D dose distributions are built in a discrete fashion by delivering the dose spot-by-spot
and energy “layer-by-layer” [35, 36]. Thus, an individual spot acts as the building block for the
creation of 3-D dose distributions [58]. In addition, the spot distribution map may provide
information that helps detect errors in treatment plans.
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Figure 3.1 Scanning Spot Nozzle and the spots pattern.(A)Scanning spot Nozzle(B)Spots cluster
pattern.(C)Small spot cluster(Red spots)
In our clinical practice, we define groups of spots constituting of the projection of proton
spots position on x-y plane as clusters (Figure 3.1B).Some of clusters with small spots amounts
are usually hard to see with the naked eye. However, small clusters sometimes signify a high
dosage area which must be managed (Figure 3.1C). Now we will discuss an algorithm used in
the analysis of clusters. A tool based on this algorithm could provide a warning for physicists
and dosimetrists to notice these small clusters and optimize treatment plans.
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3.3

Method And Material:
From 2014-2016, there were 1,241 treatment plans delivered to patients in PTCH. The plans

were used to acquire the minimum number of spots within clusters for each treatment site.
Normally if the number of spots in one cluster is smaller than the minimum number designated
in a treatment plan, the cluster is considered as a small spot cluster and will be highlighted within
the treatment plan. Forty different treatment plans, each having been revised during the treatment
process, have been used to validate a small spot cluster analysis algorithm.
3.3.1 Transfer Spots Distribution Maps To Matrices
The spots distribution maps are drawn from the dicom files exported by the treatment
planning system (Figure 3.2A). The proton spots distribution position in millimeters on x-y plane
are changed to Matrix x-y coordinate (Figure 3.2B). All numbers are rounded to integer
coordinate. The corresponding position in matrix are labeled as 1s and the other coordinate are
labeled as 0s.The spots distribution is changed into binarization matrix at this step. The 1s in
Matrix are components used in next step for connected-component labeling algorithm (Figure
3.2C)
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Figure 3.2 Transfer spots distribution map to matrices. A Coordinate list of spots position, B
Binary matrix acquired by the spots distribution map, C label clusters by connected-component
labeling algorithm
3.3.2 Connected-component Labeling Algorithm[59]
The connected-component labeling algorithm is usually applied to locate objects for visual
applications. The labeling algorithm categorizes the binarization matrix into different groups
using the connectivity of component neighboring the processed component. The connectedcomponent labeling algorithm searches for and labels possible candidates by dividing foreground
components into groups using their eight-connectivity relationship. Components which connect
in horizontal, vertical and diagonal directions are considered as one group (Figure 3.3A). Once
the background subtraction algorithm has segmented all groups from the background of the spots
plane, the connected-component labeling algorithm begins its process of locating groups. The
labeling algorithm collects and merges components into groups by judging the eight-connectivity
of the foreground components and adjacent neighboring components (Figure 3.3B). Subsequent
the application of the labeling algorithm, the location, size, and number of foreground groups are
ascertained, which helps to determine candidates for group detection .Connected-component
labeling algorithm is processed by Matlab R2014a imaging processing toolbox.
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Figure 3.3 (A) 1 group under 8-connection area include connected area in diagonal criteria (B) 2
clusters under 8-connected-componets criteria, red group and green group
3.3.3

Small Spots Clusters Labeled By Connected-component Labeling algorithm

The matrices generated by spots distribution map are labeled by connected-component
labeling algorithm (Figure 3.2C). The number and size of groups of each treatment plan are
recorded for analysis.

3.4 Results
3.4.1 Minim Spots Number Of Delivered Treatment Plans
Table 3.1 Minim spots number of delivered fields
Number of Spots
Head& Neck
4D throx
Throx
Prostate
Brain
PELVIS
CSI
Other

Num of Case
465
108
90
107
119
6
6
396

Mean

Max

Min

465
137
124
208
50
204
45

816
522
373
433
128
456
94
756

6
23
11
45
7
28
15
5

Table 3.1 last column shows minim spots number of treatment plans for each treatment site.
These numbers will be used as threshold for small spots clusters detection. The clusters with a
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spot number less than the minim number of corresponded treatment site is considered as small
spots clusters.
3.4.2

Statistical Relationship Between Small Spots Clusters And Errors In Proton
Treatment Plans

Of the 1,294 treatment plans tested by small spot cluster analysis, (53) contained more than
a single cluster (Figure 3.4). All (40) treatment plans that had been revised during the treatment
process had small spot clusters (Table 3.2 Revision column). Out of the (40) revised plans, (26)
failed in our quality assurance process (Table 3.2 QA Fail). Quality assurance concerning an
effective, individualized protocol during spot scanning proton treatment has been introduced in
other research reports [12, 60]. Overall processing time for the 1,294 treatment plans took one
hour, with time spent on each plan averaging 2.7 seconds.

Figure 3.4 Pie Chart of clusters amount of the treatment plans
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Table 3.2 Small spots clusters test result

Head&Neck
4D throx
Throx
Prostate
Brain
PELVIS
CSI
Other

3.5

Num of
Case
465
108
90
107
119
6
6
396

Re
port
21
6
3
0
0
0
0
10

Revi
sion
16
1
1
0
0
0
0
5

QA
Fail
10
3
2
0
0
0
0
11

Revision Rate
(%)
100%
66%
100%
N/A
N/A
N/A
N/A
100%

Discussion
Based on the results in Table 3.2, small spots clusters analysis algorithm is sensitive to three

types of error in proton treatment plans.

Figure 3.5 Mistake contouring detected by small spots clusters analysis, the blue clusters in the
left clusters map are the mistake contouring spots clusters
The first type of error is target contoured by mistake. This type of error would be hard to
check manually. The small spots clusters analysis algorithm is able to detect this type of error in
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the treatment plans (Figure 3.5）.The dosage points, which is created by faulty contouring,
corresponds to the small spots clusters (blue) in the cluster map. The small spot clusters contain
less spots than the minim spots number inside clusters of correct treatment plans (Treatment
plans have already been approved by oncologist). Since this type of error often goes unnoticed,
the algorithm could prevent such mistakes and help correct them. All treatment plans with this
type of error are detected by the algorithm.

Figure 3.6 Treatment plans with unnecessary spots at distal end of the beam by the small spots
clusters analysis algorithm
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Figure 3.7A treatment plan with small spots cluster fail in quality assurance at distal end of
beam

Figure 3.8 Dose distribution map of Treatment plan failed in quality assurance detected by small
cluster analysis algorithm
A second problem could be detected by small spots cluster analysis algorithm is that the
treatment plans with distal points cannot pass the quality assurance process (Figure 3.6). Please
refer to our previous research report regarding quality assurance processes [60]. All of the
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reported treatment plans that cannot pass quality assurance are led by distal points in the
direction of the beam. Calculated results by TPS do not match the measurement results (Figures
3.7&3.8).The dose distribution in a high dosage area at a distal plane is of significant difference
compared to the measurement data (less than 70% of test points could pass the gamma test). For
this reason, it is a good idea to discuss this topic in the future. At the moment, a decent alert
system remains in place for medical physicists to optimize treatment plans.

Figure 3.9 Small clusters corresponding to two hot areas inside the target volume (A). The two
hot areas are outlined with red squares (B). A small spot cluster is marked by points
corresponding to the left side of figure A (B). A small spot cluster is marked by points
corresponding to the right side of figure A
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The third type of error is that there are two hot areas inside the target volume (Figure 3.9).
These types of plans are usually optimized, since treatment plans with two targets are hard to
control. This is a good reference for the medical physicist.
For treatment plans concerning the head and neck, 4D Thoracic and Thoracic, only one 1 out
of 30 treatment plans with small spots clusters were not revised. This proves that the small spot
cluster analysis algorithm is very effective for detecting error in these types of treatment plans.
No revised treatment plans were detected concerning the prostate, brain, pelvis, and CSI.
The algorithm is not as sensitive in detecting errors for these types of treatment plans.
3.6

Conclusion
The small spots cluster analysis algorithm could detect errors such as failure of quality

assurance and mistake contouring in treatment plans at a very low cost. Use of this tool can
improve the efficiency of proton treatment analysis system could reduce the cost of treatment. As
a result, its potential for future use in a clinical setting is promising.

42

4
4.1

Fast Dose Calculation By Matrix Registration Algorithm

Introduction
Proton therapy is becoming an increasingly valuable radiotherapy option for use around the

world[61]. Through this method, protons are applied to irradiate tumors. Proton therapy can
significantly reduce dose distribution to organs at risk (OARs), located distally from the tumor,
while maintaining or even increasing the prescribed dose to the tumor directly. Accuracy can be
compared with Intensity Modulated Radiation Therapy (IMRT), which uses x-rays[62],[63]. The
advantage of proton therapy is based on the fact that protons stop at a certain, energy-dependent
depth, a point recognized as the Bragg Peak[64] where they will deliver most of their energy.
The absolute dosage must be calculated via a dose calculation program according to the
energies, spot positions, and number of monitor units (MUs) in order to protect healthy tissue
and to deliver the correct dosage to the tumor. The current dose calculation program, based on
the TOPAS simulation tool, may take as long as 5 hours to retrieve a dose calculation for an
individual patient [50]. Hence, the treatment available at our center is dependent upon a
significant amount of time.
The aim of this study is to build a fast dose calculation tool, based on the matrix registration
algorithm. This method has been evaluated by measurement data collected at the MD Anderson
Proton Therapy Center.
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4.2

Material And Method:

Figure 4.1 Fast dose calculation process. A simulation model in TOPAS.B. Pre-stored dose
distribution matrices. C. Coordinate direction of the simulation model
4.2.1 General Working Process Of Fast Dose Calculation Method
1. A simulation model is built using the TOPAS simulation tool, based on the parameter in
Figure 4.1A.
2. The dose deposited to the water phantom for all proton energies (94 total) is calculated by
the simulation model using TOPAS and stored in sliced images as seen in the dose distribution
matrices (Figure 4.1B&D).
3. Dose distribution matrices of individual energy will be loaded and added together to
reconstruct a new dose distribution matrix (Figure 4.2).
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4.2.2 Simulation Model Of Individual Energy By TOPAS
TOPAS simulation tool is introduced in Chapter 1(Section 1.1.5).Simulation model is set as
following parameters. The QGSP_BIC_EMY physics list was selected to provide the accurate
dose distribution [46-48]. The parameters of the geometrical model are as displayed in Figure
4.1A. A water phantom with x, y, and z dimensions of 25 cm, 25 cm, and 35 cm was built in the
simulation. For dose calculations, the voxel has a volume of 1 × 1 × 1 mm3 in the water phantom
[49].A double Gaussian beam source model is built for this simulation. The spatial spread of
each beam source decreases as beam energy increases. The spatial spread of the first source, σ_1,
was set to range from 5.2 mm to 11.2 mm for beam energies. For energies between 74.5 MeV
and 150.0 MeV, the spatial spread of the second source, σ_2, was set to range from 12.5 mm to
27.2 mm. For energies above 150.0 MeV, the second source was not needed. For energies lower
than 80 MeV, the weight for the second source is set as 0.12. For energies from 80 MeV to 150
MeV, the weight of the second source is 0.08 [40, 51, 52].3D dose distribution of individual
energy could be calculated by TOPAS by this simulation model.
4.2.3 Pre-stored Data Set
A data set includes the dose distribution matrices of all (94) total proton energies and is
stored for matrix registration and reconstruction. Multiple dose distribution profiles are stored by
matrices (Figure 4.1D). The new and decisive dose distribution matrix for a specific treatment
plan is reconstructed by adding these individual dose distribution matrices together.
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4.2.4 Matrix Registration And Reconstruction

Figure 4.2 Fast dose caculation process
4.2.4.1 Definition Of Spot Position And Dose Distribution Matrix Registration Method
The longitudinal (z-direction) position of a spot is defined as the point where the integral
depth dose (IDD) of a spot falls under 90% of the Bragg peak. This location is determined by x-x
and y-y steering magnets in the lateral (x-y) direction and spot energy in longitudinal (z)
direction (Figure 4.1C). The spot coordinates (x,y) are located at the position where the center of
the dose distribution matrices of individual energy (SingleMatrix) locates in the result matrix
(ResultMatrix). Dose distribution matrices of individual energy (SingleMatrix) are registered in
the result matrices (ResultMatrix) by matching the center of the SingleMatrix to the spot position
in the ResultMatrix (Figure 4.2A).
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4.2.4.2 Matrix Reconstruct Method
In each patient’s treatment plan, information regarding the spot coordinates and energy
levels are drawn from the TPS dicom file. The dose distribution matrices of individual energy
(SingleMatrix) are drawn from pre-stored data sets (Figure 4.2C). Dosage per unit is calculated
by IDD measurement files for each energy (Figure 4.2B). These IDD measurement files are the
commissioned data of the proton delivery system. Each individual dose distribution matrix is
shifted to the position according to spot positions (Figure 4.2A). The result distribution matrix
for a specific treatment plan is reconstructed by an equation (4.1) .Because the size of the
individual dose distribution matrix (SingleMatrix) is 250×250 pixels, the coordinate range of
SingleMatrix in the ResultMatrix is (x-125: x+125, y-125: y+125).
ResultMatrix [x-125: x+125, y-125: y+125] = ResultMatrix [x-125: x+125, y-125: y+125]
+SingleMatrix

(Eq 4.1)

Where:


ResultMatrix is the new dose distribution matrix used to determine specific depth in
a treatment plan.



The spot coordinate(x,y) is the position where the center of dose distribution matrix
of individual energy(SingleMatrix) locates in the result matrices (ResultMatrix).



SingleMatrix is the dose distribution matrix of individual energy at specific depth. It
is a 250x250 pixel matrix which corresponds to the sizable area in ResultMatrix.

4.2.5 Dose Calculation Results Validated By Clinical Treatment Plan
Quality assurance measurements contain two components: [1] dose measurements using the
treatment fields delivered through the electronic medical record (EMR) system (Mosaiq versions,
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1.5–2.4; Elekta Medical Systems, Sunnyvale, CA, USA) in the quality assurance mode and
through the accelerator control system (ACS) in the treatment mode; and [2] extra dose
measurements of depth dose and two-dimensional (2D) dose distributions at altered depths in the
physics mode of the ACS. The measurement is implemented by Matrixx (MatriXXTM,
Scanditronix Wellhofer, Schwarzenbruck, German) [65]. For methods used by Matrixx, refer to
Section 1.1.6. The ResultMatrix, or the calculation result, will be validated by comparison to the
measurement results acquired by the Matrixx gamma test (refer to Section 1.1.6).
4.3

Result

4.3.1 Calculation Results Validated By IDD Measurement Data
The integral depths of dosage (IDD) for all energies are calculated by the fast dose
calculation method. The calculation data is compared with the measurement data acquired from
commission data of the proton delivery system (Figure 4.3).All differences are within 3%. This
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accuracy satisfies our clinical requirement, which is a 3% dosage difference between calculation
and measurement data.

Figure 4.3 IDD data validation

4.3.2 Calculation Results Validated By Lateral Dose Distribution
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Figure 4.4 Schematic of lateral does distribution

Figure 4.5 Lateral dose distribution validation
The reconstructed dose matrix in an x-y plane is validated by lateral dose distribution data
acquired from commission data of the proton delivery system (Figure 4.4). The tolerance for this
validation is 10-1 cGy. All differences for reconstructed dose matrices are compared to the
measurement data and are within 3% (Figure 4.5). This level of accuracy satisfies our clinical
requirements.
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4.3.3 Calculation Results Validated By Clinical Plan
The calculation results (Figure 4.6A&C) are compared with measurement data from a
treatment plan acquired by Matrixx (Figure 4.6B&D). According to Figure 4.6(E&F), the gamma
test pass rate under the criteria of 3 mm – 3% amounts to 98.5%, which is much higher than our
clinical requirement (Figure E&F).
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Figure 4.6 Caculation result validated by measurement data
Table 4.1 Calculation results validated by different treatment sites
Treatment site
Brain
Head&neck
Lung

Gamma pass rate
99.30%
98.50%
90.20%

Calculation results are validated by different treatment sites. The pass rates of these
treatment plans are higher than 90% according to 3 mm – 3% criteria (Table 4.1).
4.3.4 Computational Efficiency Assessment
The average calculation time, based on (4) treatment plans, is 20 minutes per plan.
Calculation time varies according to the number of spots found in the treatment plans. Time used
is lower than the time required using tradition method in TOPAS, which is approximately (5)
hours per plan [40].
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4.4

Discussion

4.4.1 Dose Calculation Based On TOPAS Can Be Implemented On Personal Computer With
Satisfying Efficiency
As reported by previous clinical publication, the calculation time for a beam during a typical
head and neck exam is (4) CPU hours per million particles based on a sever (2.8-2.9 GHz Intel
X5600) by TOPAS [40]. Fast dose calculation method is implemented on a personal computer
(4GHz Intel i7-6770), where calculations for one treatment plan can be completed within 20
minutes. Gamma test results between calculation data and measurement data can satisfy our
current clinical requirement 3mm -3% (90% pass rate).
4.4.2 The Method With More Flexibility
Based on the advantages of TOPAS, there is more flexibility with this method than with
other analytical methods. The features of the model, such as SSD, phantom material, and
architecture can be easily modified and tested. They all can be validated by common
measurement data, including IDD and lateral dose distribution data.
4.4.3 Future Work
The proposed water phantom would take the place of the water phantom block used in daily
measurement taking. In the future, this model could then be replaced by a patient phantom which
has been reconstructed from dicom files. Therefore, this method has the potential to generate
better results.
4.5

Conclusion
We have shown the advantages of the fast dose calculation method based on TOPAS. This

method can be integrated for use in clinical procedures. Both efficiency and accuracy match the
current standard clinical requirements. The fast dose calculation method can be validated by the
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various treatment sites from proton treatment plans. A total of all validation results would satisfy
clinical requirements. It is reasonable to conclude that the fast dose calculation method in proton
treatment analysis system can reduce labor costs and improve efficiency in both clinical practice
and the academic arena.
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5

Proton Treatment Monitoring Through Circulating Tumor Cell Detection
And Isolation By Regional Automatic Threshold And Image Registration
Algorithm

5.1

Introduction
Proton treatment usually lasts 3 months. The status of a tumor could change significantly

during this time. According to current research, Circulating Tumor Cells (CTCs) are considered
one of the best choices for monitoring tumor status. The mechanism describing how
nanostructured embedded microchips could immobilize and isolate CTCs was discussed in our
previous research report [24]. A CTC analysis program, based on regional automatic threshold
and image registration algorithms, could automatically detect and isolate CTCs from
nanostructured embedded microchips has been developed for monitoring the status of tumors
during the proton treatment process.
Nikon Digital Microscope and Laser Capture Microdissection (LCM) are systems used to
detect and isolate CTCs from microchips. The Nikon Digital Microscope system scans highquality images to detect CTCs on nanostructured embedded microchips. The LCM system could
provide qualified genetic analysis of tumor cells [66, 67]. It is widely used in rare cell isolation,
heterogeneity of tissue separation, and circulating DNA separation [68] [69].
The degree of automation in the Nikon Digital Microscope and LCM systems is very low,
making them valuable in clinical practice. Before the CTC analysis program developed,
researchers were required to manually recognize and isolate CTCs from thousands of cells on the
microchips. This resulted in labor that was time-consuming and tedious, yielding subjective and
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imprecise results. Therefore, these systems could aid in the efficiency of monitoring the tumor
status during proton treatment.
5.2

Materials And Methods:

5.2.1 Materials
5.2.1.1 Q Program
Q Programming language is applied directly in order to control computer operation. The Q
program script will link to the keyboard of a computer to operate software for the Laser Capture
Microdissection system (LCM). Together, Q program script and the LCM software control a
laser used to cut out a specific area based on input coordinates.
5.2.1.2 Laser Capture Microdissection System (LCM)
The Laser Capture Microdissection system (LCM) is used to isolate single CTCs from
microchips for molecular analysis. LCM isolates single CTCs with genetic material of a high
purity for second-generation deep gene sequencing [69]. LCM includes the following devices:
● Nikon Eclipse high resolution immunofluorescence microscope
● Hamamatsu C11440 high resolution camera
● Nikon Eclipse Ti-E high quality (inverted research) microscope
● Arcturus® LCM system
● Q programing language compiler
● PLGA NanoVelcro Chips
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Figure 5.1 Micro Laser Dissection on micro-chip
5.2.2 Method:
There are 4 steps involved in monitoring tumor status via CTC analysis:


The imaging condition parameter must be acquired in order to calculate the intensity
adjustment factor (IAF) of immunofluorescence under different exposure times.



The target area of the microchips must be scanned. High resolution CTC images are
acquired for CTC analysis.



CTCs are then detected in the images using a regional automatic threshold algorithm.
Tumor status will be reported to medical professionals in order to create new
treatment plans if morphological features related to tumor status, such as vsn (very
small nuclear) CTCs are detected.



Isolation of CTCs on the chips is completed by using an image registration
algorithm. Positioning of the CTCs is acquired in Step 3: Single CTCs are harvested
in this step and could be used for molecular analysis while monitoring tumor status.
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5.2.2.1 Imaging Condition Parameter
Table 5.1 Imaging condition testing List
Concentration
\Time
5 mins
10 mins
30 mins
1h
2h

01:00.
5
1
A1
B1
C1
D1
E1

1:01

1:02

1:00

2
A2
B2
C2
D2
E2

3
A3
B3
C3
D3
E3

4
A4
B4
C4
D4
E4

A
B
C
D
E

Exposure time is an important parameter on acquiring fluorescence image. The relationship
between fluorescence intensity and exposure time are clarified by the test. Because the intensity
adjust factor (IAF) is a relative value, varies in different laboratories. CTC characteristics include
the size of the nucleus, cell size is related with cell immobilization methods, solution
concentration and other experimental conditions. Intensity adjust factor should be re-calibration
in different experimental condition.
Standard Immunofluorescence test are applied to 3-color immunocytochemistry (ICC)
protocol for equivalent staining of DAPI, FITC-labeled anti-CK, TRICY-labeled anti-CD45
[27].The immunofluorescence intensity is related to the antibody concentration and stain time.
The intensity adjust factor (IAF) is calculated by slope of linear relationship equation of
immunofluorescence and exposure time.
5.2.2.2 Automatic Scan Images On Nickon 90i Imaging System
The parameters setting according our previous test [70].Intensity adjust factor (IAF) is based
on imaging condition parameter in 5.2.2.1(Figure 5.2).
High resolution images are scanned on the chip based on following scanning parameters:
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The fluorescence of target area is set from 30 to300 and the circularity of target area is set
from 0.65 to 1.00.


TRICT<200×IAF of TRICT



FITC > 200×IAF of FITC



DAPI>200×IAF of DAPI
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Figure 5.2 Images scanned by Nickon imaging system
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The image in Figure 5.2 includes three channels:


Green channel stands for FITC which is conjoined with CTCs membrane biomarker



Red channel stands for TRICT which is conjoined with white blood cell



Blue channel stands for DAPI which is nuclear biomarker

5.2.2.3 Regional Automatic Threshold Algorithm
All algorithms are implemented in Matlab R2014a.The automatic threshold algorithms is a
function from Matlab imaging toolbox.
Regional automatic threshold is applied on scanning images. The algorithm applies
automatic threshold on all three channels of the images and then merge the region of interest
(ROI) of FITC and DAPI which represent for cell membrane and nucleus (step 2 equation). Then
enlarge the area by 5 times to acquire the target area.5 times area is applied here based on the
average distance between cells is five times of cell diameter. Automatic threshold method are
applied to individual area for segmenting the cell structure locally.
The algorithm could be described as following steps.
1. Apply automatic threshold to 2 channels (Figure 5.3)
2. ROI(Region of interest)= (DAPI∩FITC ∩┐TRICY)*5(Figure 5.4)
3. Apply Automatic threshold on Individual ROI for each channel (Figure 5.4)
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4. Register the ROI in Figure 5.4 by position to the original image, CTCs position are
marked out (Figure 5.5)

Figure 5.3 Automatic threshold on FITC and DAPI channel
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Figure 5.4 Region of interest result by merging information from FITC and DAPI area

Figure 5.5 CTCs detected by CTCs analysis program, the yellow outline is cell membrane, green
outline is the cell Nucleus
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5.2.2.4 CTC Isolation Algorithms
Images with marked CTCs position (Xp,Yp), Figure 5.6A. Cell center position (Xp,Yp) is
acquired by regional Automatic Threshold.
Cell center position (Xp,Yp) registered on the full scan image position (Xi,Yi) by following
equation(Figure 5.6B):
Xi= Xp *N
Yi= Yp*M
(M,N) is the image scan sequence number acquired from the scan images files in Figure 5.6B.
The full scan image position of (Xi,Yi) is registered on the chip position (X,Y) by the following
equation (Figure 5.6C):
X= ((Xi-X0)/123) + 294
Y= ((Yi- Y0)/123) + 839
(Xi,Yi) is the coordinate of the full scan image under the C11440 high resolution camera.
(X0,Y0) is the reference point and (X, Y) is the coordinate that will be used for registration on the
chip. (294,839) is the reference point on the LCM screen.
(X,Y) is based on the screen coordinate; the resolution of the screen will affect the
registration on the LCM (for example, every time the screen changes, the reference point on the
LCM will also change).
Q program script will operate the laser to cut a circle with (X, Y) as the center on the
microchip. CTCs on the cut area will be collected by caps covering the microchip. The caps
contain a sticky substance that clings to the surface of the microchips.
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Figure 5.6 A is the target cells detected by the detection system. The cell center position is
marked out by a binary matrix (black area) in local image. B is the cell’s center position
registered on the full scan image of the chip. C is the cell’s center position on the LCM system.
5.2.2.5 CTCs Viability Validation By Housekeeping Genes Test
Cells on the caps will be processed by the Qiagen whole genome amplification (WGA) kit.
The genetic material of the cells will be amplified by the kit for housekeeping genes test. A
multiplex PCR reaction of a panel of 8 housekeeping genes (located at different chromosomes) is
employed to validate CTCs viability. After the multiplex PCR reaction, only those samples
which exhibited positive readout (as in, more than 5 out of the 8 housekeeping genes are
positive) will be considered as qualified cells.
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5.3

Result And Discussion

5.3.1 Imaging Condition Parameter
According to the results, a regression curve is plotted and shown in Figure 5.7 and Figure
5.8. Fluorescence intensity has a significant correlation to exposure time. The coefficient ‘a’
correlates to the density of the antibody on the cell membrane. This coefficient ‘a’ is issued as
the intensity adjust factor (IAF). The P-value is low for y 0 because it is related to the
background condition variable. The values of y 0 equal the background value when the exposure
time is 0. This is a critical value for further image processing, as some of the criteria for CTC
detection states that FITC intensity shall double that of the background intensity. A similar
regression curve of DAPI is shown in Figure 5.9.

Figure 5.7 Exposure time and the correlation curve of the TRICY fluorescence intensity
Equation: Polynomial, Linear
f = y0+a×x
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Table 5.2 TRICY fluorescence equation factor
R

Rsqr

Adj Rsqr

Standard Error of
Estimate

y0

0.9971
Coefficient
29.7602

0.9942
Std. Error
29.0862

0.9939
t
1.0232

76.7869
P
<0.3173

a

3.7178

0.0605

61.4532

<0.0001

Figure 5.8 Exposure time and the correlation curve of the FITC fluorescence intensity

Equation: Polynomial, Linear
f = y0+a×x
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Table 5.3 FITC fluorescence intensity equation factor

y0
a

R

Rsqr

Adj Rsqr

Standard Error of
Estimate

0.9925
Coefficient
81.5271
0.6521

0.9851
Std. Error
8.2309
0.0171

0.9844
t
9.905
38.0924

21.7294
P
<0.0001
<0.0001

Figure 5.9 Exposure time and the correlation curve of the DAPI fluorescence intensity
f = y0+a×x
Table 5.4 DAPI fluorescence intensity equation factor

y0
a

R

Rsqr

Adj Rsqr

0.9941
Coefficient
56.773
58.3183

0.9882
Std. Error
95.1617
2.4106
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0.9865
t
0.5966
24.1929

Standard Error of
Estimate

169.384
P
<0.5696
<0.0001

5.3.1.1 Relationship Between Imaging Result And Antibody Concentration
The antibody concentration rate (1X, 2X) is based on ThermoFisher cytokeratin standard dilution
procedure.

Figure 5.10 FITC Area/DAPI Area Curve
Because the FITC label on cytokeratin shows the reaction of an antibody combining with the
antigen on the cell membrane, the FITC area represents the membrane with cytokeratin protein.
DAPI is always applied to this area. According to principles of DAPI application, we assume
that the nucleus and the area marked by DAPI is a fixed value for each cell under any given
condition. The FITC/DAPI rate stands for the cytokeratin relative to the stained area. According
to Figure 5.10, the FITC/DAPI rate peaks at 40 minutes. A comparison of the 0.5X concentration
to the 1.0X concentration of an antibody shows that a higher concentration could enlarge the
stain area. However, a 1.0X concentration is sufficient since the FITC stain area showed no
improvement after the application of a 2.0X concentration antibody.
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5.3.1.2 Relationship between Antibody Concentration and Background Fluoresce Intensity
The intensity difference between FITC and background TRITC characterize the signal noise
ratio (Figure 5.11). The value reaches its peak at 40 mins. The 2X concentration antibody
solution did the best signal noise ratio. The curve varies randomly after 40 minutes.2X
concentration antibody could be used to acquire best signal. The staining time shall be limited
within 40 minutes.

Figure 5.11 Difference between FITC and Background TRICY
5.3.1.3 Relationship between Antibody Concentration and Non-specific Staining
According to Figure 5.12, the TRICY fluorescence intensity from a tumor cell reflects nonspecific staining on the cell membrane due to the non-existence of white blood cells. Nonspecific staining is the reason why TRICY, a white blood cell biomarker, may combine with
CTCs. This phenomenon has always existed, but immunophenotype can still be distinguished if
the FITC intensity divided by the TRICY intensity is higher than two. The ratio reaches its peak
at 40 minutes, decreasing significantly after that. The highest ratio appears when the antibody
concentration is at 1.0X.
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Figure 5.12 FITC/TRICY ratio
5.3.1.4 Imaging Conditions Required By CTCs Analysis Program
Intensity adjust factor (IAF) for all biomarkers shall be acquired and applied to adjust
fluoresce intensity according to the exposure time. The staining time shall be within 40 minutes
to get best signal /noise ratio. Our current antibody concentration (1X) could acquire best CTCs
staining signal and prevent non-specific staining. This concentration of antibody will be required
for any input images to the CTCs analysis program.
5.3.2 Region Of Interest Detection
The circles displayed in Figure 5.13 marked out the regional of interest. CTCs in these ROI
will be detected by regional automatic threshold algorithm.
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Figure 5.13 Region of Interest, the yellow outline marked out the segmented region
The features of CTCs are acquired by a regional automatic threshold. According to our
analysis of the morphological features of CTCs the sub-classification of prostate cancer, based
on circulating tumor cells classified by nuclear size, reveals the existence of very small nuclear
circulating tumor cells in patients having visceral metastases.
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Figure 5.14 visceral metastasis, in which vsnCTCs account for the largest percentage of cells
(65%)[71].

The revelation between vsnCTC(very small nuclear) and visceral metastases was reported in
our previous clinical research publication[71].VsnCTC were found to be elevated in patients
with visceral metastases compared with without vsnCTC(0.3660.69 vs 1.9563.77 cells/mL
blood; P<0.001)(Figure 5.14). CTCs automatic analysis program will signal physicians to
modify proton treatment plan whenever vsnCTC are detected.
5.3.3 CTCs Automatic Isolation
5.3.3.1 Speed Of Cell Harvest
The average time spent on 1 chip is 30 minutes by human operation versus 15 minutes via
the automatic analysis program. If there are two LCMs, it is possible for one technician to
operate two machines in the same time thereby improving the efficiency two fold.
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5.3.3.2 CTCs Viability Validation

Figure 5.15 A is LCM standard micro-chip. B is cut area on LCM system. C is the target cell
with green immunofluorescence on cut off area is housekeeping test result of the cut off cells.
According to Figure 5.15B, the red circle area is the area cut off from the chip by laser.
The target cell with immunofluorescence (Figure 5.15C) is shown inside the cut area. According
to Figure 5.15D, the six cells cut by the system (all of the cells with the exception of channel 3)
are considered qualified cells for further molecular analysis. The results prove that the CTCs
automatic analysis system could adequately protect cell viability for tumor status monitoring.
5.4

Conclusion
CTCs can be effectively detected by a regional automatic threshold algorithm under the

conditions describe in section (5.3.1.4). Characteristics (such as very small nucleus) can be used
to monitor the metastasis of a tumor. Medical doctors are then able to adjust treatment plans
according to the information received from a tumor status. The automatic LCM control program
greatly improves efficiency during cell harvesting, while cell viability remains well protected
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during molecular analysis. Molecular features could provide additional information regarding
tumor status. Overall, the CTC analysis program in proton treatment analysis system is valuable
in monitoring tumor status through its use of morphological features and through isolation of
single high viability CTC.
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6

Conclusion

This study focused on applying automatic analysis technology to proton therapy treatment.
Segmentation and registration algorithms (including matrix registration by proton spot positioning,
connected-component algorithms, regional automatic threshold, and image registration by CTC
positioning) are used to analyze proton treatment plans. The main objective is to reduce labor and
time during the treatment process.
The biggest range shifter correction factor is 0.11, which could significantly affect the dose
calculation results. The mean dose difference (between the range shifter model simulation results
and the measurement results acquired by the Bragg’s peak chamber) is within 1.3%. This dose
difference satisfies our clinical requirement of being within 3%.
Small spot cluster analysis is able to detect 100% of the revised treatment plans involving
sites such as the head and neck, thorax, and 4D thorax. Error revision of treatment plans could be
completed before measurements are taken with the help of small spot cluster analysis, thus saving
time and labor.
Fast dose calculations based on pre-stored simulation data in matrices can be used to
reconstruct new dose distribution matrices, according to the position of spots in imaging seen in
the treatment plan. Calculations could be completed in less than 30 minutes per beam on a personal
computer and may be deployed from any location. Even if the original model is modified, a new
data set could be built within a few days. The dose calculation results are validated by clinical
treatment plans. Gamma test pass rates for all treatment plans are higher than 90%, which satisfies
clinical requirements.
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Circulating Tumor Cell analysis could provide feedback for physicians to adjust treatment
plans without requiring invasive screening methods. VsnCTCs account for the largest percentage
of cells (65%) in visceral metastasis. The CTC automatic analysis program could guide medical
professionals in adjusting treatment plans by detecting features such as vsnCTCs.
Overall, the automatic proton treatment analysis system greatly improves the efficiency during
the proton treatment process. Perhaps the largest contribution is the conservation of labor and
redundant work, making it highly valuable in a clinical setting.
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Appendix
Table 0.1 Fluorescence intensity vs. Exposure Time
Fluorescence intensity vs.
Exposure Time
TRIC

FITC
Y

Exposure
Time（ ms）

168.6

30

266.4

60

359.8

90

460.2

120

157.7

600

150

201.3

671

180

223.0

877

210

234.6

932

240

257

1009

270

278

1086

300

320

1150

330

346

1280

360

350

1456

390

390

1513

420

401

1762

450

426

1871

480

424

2011

510

73.45
1
93.09
7
129.0
1

1
143.1

1

5

8

2

2

1

87

441

2069

540

467

2130

570

481

2279

600

519

2866

720

574

3191

810

641

3258

900

725

3585

990
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